BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

NEW YORK, NY / ACCESSWIRE / March 10, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=70225&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on BioNTech SE(BNTX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESSWIRE / March 9, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=70135&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on BioNTech SE(BNTX) should contact Levi & Korsinsky about pending Class Action - BNTX

BENSALEM, Pa. , March 8, 2024 /PRNewswire/ -- Law Offices of Howard G.

BNTX Investors Have Opportunity to Lead BioNTech SE Securities Fraud Lawsuit

NEW YORK, NY / ACCESSWIRE / March 8, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=69977&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 12, 2024 in BioNTech Lawsuit - BNTX

NEW YORK, NY / ACCESSWIRE / March 8, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=69958&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioNTech SE(BNTX) Shareholders

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=69884&wire=1 or contact Joseph E. Levi, Esq.

Shareholders That Lost Money on BioNTech Se (BNTX) Should Contact Levi & Korsinsky About Pending Class Action - BNTX

RADNOR, Pa. , March 7, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioNTech SE ("BioNTech") (NASDAQ: BNTX).

Kessler Topaz Meltzer & Check, LLP Reminds BioNTech SE Investors of Important Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=69873&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies BioNTech SE Investors of a Class Action Lawsuit and Upcoming Deadline - BNTX

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=69856&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of BioNTech SE(BNTX) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=69756&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds BioNTech SE Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 12, 2024 - BNTX

Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the Management Board of BioNTech. As of July 1, 2024, Sean Marett will continue as a specialist advisor to the Company at least until the end of the year. A new Chief Commercial Officer will be announced by the end of March 2024. Sean Marett's responsibilities as Chief Business Officer are beeing gradually transferred to James Ryan, Ph.D., Chief Legal Officer, who will also take on the role of Chief Business Officer of BioNTech at the end of the transition phase and upon Sean Marett's retirement.

BioNTech Announces Planned Retirement of Sean Marett

LOS ANGELES, CA / ACCESSWIRE / March 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ:BNTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

FINAL DEADLINE NOTICE: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm

Exelixis

Neurocrine Biosciences

Biotech stocks have always been high-risk and high-reward, with the futures and fortunes of companies often decided with a single successful drug trial or Federal Drug Administration (FDA) approval. The right company can yield extravagant returns for the lucky or prudent investor.

3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success

LOS ANGELES, CA / ACCESSWIRE / March 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ:BNTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm

MAINZ, Germany, March 6, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024

NEW YORK , March 5, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, both dates inclusive (the "Class Period"), of the important March 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased BioNTech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

BNTX IMPORTANT DEADLINE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=69360&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioNTech SE (BNTX) Shareholders

LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ:BNTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=69314&wire=1 or contact Joseph E. Levi, Esq.

Shareholders That Lost Money on BioNTech SE(BNTX) Should Contact Levi & Korsinsky About Pending Class Action - BNTX

NEW YORK , March 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioNTech SE. Shareholders who purchased shares of BNTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Reminds BioNTech SE Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 12, 2024 - BNTX

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=69253&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on BioNTech SE (BNTX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Aurora Cannabis

AngioDynamics

APA Corporation

Franco-Nevada C

Gilead Sciences

Xcel Energy

Ordinarily, you'll want to avoid excessively red-stained ideas. Although certain exceptions might be made for these oversold stocks ready for rebound.

Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound

LOS ANGELES, CA / ACCESSWIRE / March 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ:BNTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

MARCH 12 FINAL DEADLINE: The Schall Law Firm Encourages Investors in BioNTech SE with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=69142&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against BioNTech SE (BNTX) Seeking Recovery for Investors - Contact Levi & Korsinsky

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioNTech SE (“BioNTech”) (NASDAQ: BNTX). The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of BioNTech' s materially misleading statements and omissions to the publ.

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Against BioNTech SE (BNTX) and Urges BNTX Investors with Substantial Losses to Contact the Firm

News for BioNTech SE Stock (BNTX)